Anaplastic Large Cell Lymphoma (ALCL) is a distinct type of non-Hodgkin lymphoma, falling under the umbrella of peripheral T-cell lymphomas. What sets it apart, right from the get-go, is its strong expression of a marker called CD30, often referred to as the Ki-1 antigen. It's a less common lymphoma, but its characteristics are quite specific.
When we talk about the pathology of ALCL, we're looking at tumor cells that are generally large and exhibit a variety of shapes – they're described as pleomorphic. You'll often find nuclei that are large and irregular, and sometimes, you can spot what are called 'hallmark cells.' These are cells with a distinctive horseshoe or kidney-bean shape to their nucleus, almost like a signature. These cells tend to spread in a diffuse or nest-like pattern, often along lymphatic sinuses or between follicles.
A significant piece of the ALCL puzzle, especially in children, involves a specific chromosomal translocation, t(2;5)(p23;q35). This translocation leads to the formation of a fusion gene, NPM1-ALK. This genetic abnormality is so crucial that it forms the basis for classifying ALCL into two main subtypes: ALK-positive (ALK+) and ALK-negative (ALK-). The presence or absence of ALK expression profoundly influences the disease's behavior and how patients respond to treatment.
Clinically, ALCL can present with systemic symptoms like fever, night sweats, and weight loss. It has a tendency to spread beyond the lymph nodes, affecting organs such as the skin, lungs, bones, and liver. In children, it's not uncommon for the disease to be diagnosed at more advanced stages (III-IV).
Treatment strategies primarily revolve around chemotherapy. For cases that are relapsed or refractory, options like vinca alkaloid maintenance therapy or hematopoietic stem cell transplantation might be considered. Targeted therapies are also increasingly important, including CD30 monoclonal antibodies and ALK inhibitors. The prognosis is closely tied to factors like ALK expression status, the stage of the disease at diagnosis, and the presence of minimal residual disease after treatment.
It's worth noting that ALCL can manifest with different morphological patterns. Beyond the common type, there are subtypes like the lymphohistiocytic pattern, small cell pattern, Hodgkin-like pattern, and composite patterns. Recognizing these variations is key to accurate diagnosis and management, as they can sometimes be mistaken for other conditions. The immune phenotype also plays a vital role, with characteristic expression of T-cell antigens and CD30, alongside the crucial ALK staining which, in ALK+ cases, often shows a distinctive pattern in the cytoplasm, nucleus, and nucleoli due to the NPM-ALK fusion protein.
